癸卯年首场泌尿男生殖系肿瘤的国际大秀——2023年美国临床肿瘤学会（ASCO）泌尿男生殖系肿瘤研讨会（ASCO-GU 2023）将于当地时间2月16~18日在美国旧金山举行。
癸卯年首场泌尿男生殖系肿瘤的国际大秀——2023年美国临床肿瘤学会（ASCO）泌尿男生殖系肿瘤研讨会（ASCO-GU 2023）将于当地时间2月16~18日在美国旧金山举行。在尿路上皮癌领域，阿替利珠单抗单药或联合化疗用于mUC一线治疗的IMvigor130研究将报道最终OS结果，KEYNOTE-057研究则将探讨帕博利珠单抗用于卡介苗无应答高危NMIBC；此外还有多项值得关注的研究入围快速摘要环节。
Oral Abstract Session B:Urothelial Carcinoma
摘要号：LBA440
Atezolizumab(atezo)+platinum/gemcitabine(plt/gem)vs placebo+plt/gem for first-line(1L)treatment(tx)of locally advanced or metastatic urothelial carcinoma(mUC):Final OS from the randomized Phase 3 IMvigor130 study.
阿替利珠单抗（atezo）＋铂类/吉西他滨（plt/gem）对比安慰剂＋plt/gem用于局部晚期或转移性尿路上皮癌（mUC）一线（1L）治疗（tx）：随机3期IMvigor130研究的最终OS结果。
摘要号：LBA441
Final overall survival(OS)analysis of atezolizumab(atezo)monotherapy vs chemotherapy(chemo)in untreated locally advanced or metastatic urothelial carcinoma(mUC)from the Phase 3 IMvigor130 study.
阿替利珠单抗（atezo）单药治疗对比化疗（chemo）用于未经治疗局部晚期或转移性尿路上皮癌（mUC）的3期IMvigor130研究最终总生存期（OS）分析。
摘要号：LBA442
Pembrolizumab(pembro)monotherapy for patients(pts)with high-risk non–muscle-invasive bladder cancer(HR NMIBC)unresponsive to bacillus Calmette–Guérin(BCG):Results from cohort B of the phase 2 KEYNOTE-057 trial.
帕博利珠单抗单药治疗用于卡介苗（BCG）无应答的高风险非肌层浸润性膀胱癌（HR NMIBC）患者：2期KEYNOTE-057试验队列B结果。
摘要号：LBA443
Extended follow-up results from the CheckMate 274 trial.
CheckMate 274试验的长期随访结果
Rapid Abstract Session:Urothelial Carcinoma
摘要号：LBA445
Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non–muscle-invasive bladder cancer:A prospective study.
非肌层浸润性膀胱癌患者在二次电切前采用尿液细胞游离DNA（ctDNA）进行微小残留病灶（MRD）监测：一项回顾性研究
摘要号：446
Randomised phase II trial of adaptive image guided radiotherapy in muscle invasive bladder cancer:Late toxicity and cancer outcomes.
图像引导放疗（IGRT）用于肌层浸润性膀胱癌的随机II期试验：远期毒性和癌症结局。
摘要号：447
Co-primary endpoint analysis of HCRN GU 16-257:Phase 2 trial of gemcitabine，cisplatin，plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer(MIBC).
HCRN GU 16-257的共同主要终点分析：吉西他滨、顺铂联合纳武利尤单抗用于肌层浸润性膀胱癌（MIBC）选择性保膀胱患者的2期研究。
摘要号：448
HCRN GU14-188:Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer.
HCRN GU14-188：帕博利珠单抗联合化疗用于T2-4aN0M0尿路上皮癌新辅助治疗的Ib/II期研究
摘要号：449
Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer:An inverse probability treatment-weighted analysis.
全骨盆放疗用于肌层浸润性膀胱癌患者治疗的获益：一项逆概率治疗-加权分析。
摘要号：520
Primary analysis of TROPHY-U-01 cohort 2，a phase 2 study of sacituzumab govitecan(SG)in platinum(PT)-ineligible patients(pts)with metastatic urothelial cancer(mUC)that progressed after prior checkpoint inhibitor(CPI)therapy.
戈沙妥珠单抗（SG）用于检查点抑制剂（CPI）治疗进展、铂类（PT）不耐受的转移性尿路上皮癌（mUC）患者的2期TROPHY-U-01研究队列2初步分析。
京公网安备 11010502033352号